Supernus Invests $400 Million to Acquire New Parkinson’s Assets from Adamas
On October 11th, Maryland-based Supernus Pharmaceuticals announced that it is acquiring Adamas Pharmaceuticals in an all-cash deal amounting to approximately $400 million. This roughly comes out to $9.10 per share, which includes an upfront payment of $8.10 per share.
An additional $1.00 contingent value right will be paid if Adamas' top-selling Parkinson's drug, Gocovri, achieves certain sales milestones. Specifically, the first CVR worth $0.50 per share, is payable if net sales touch $150 million in any four consecutive quarters between closing and the end of 2024. The second CVR is payable if the drug makes $225 million in any four consecutive quarters between closing and the end of 2025.
An additional $1.00 contingent value right will be paid if Adamas' top-selling Parkinson's drug, Gocovri, achieves certain sales milestones. Specifically, the first CVR worth $0.50 per share, is payable if net sales touch $150 million in any four consecutive quarters between closing and the end of 2024. The second CVR is payable if the drug makes $225 million in any four consecutive quarters between closing and the end of 2025.
GO Prime with only $1.49 now
LATEST
CellTech Accelerator and Cyto-Facto Inc. Forge Strategic Partnership to Advance CGT Industry Growth
2024-04-29
ImmunityBio’s ANKTIVA® Granted FDA Approval: Breakthrough IL-15 Receptor Agonist First-in-Class for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
2024-04-24
Takeda, Astellas, and Sumitomo Mitsui Banking Declare Agreement For Early Drug Discovery Program Incubation in Joint Venture
2024-04-23